Flow Neuroscience has secured FDA approval for FL-100, the first at-home brain stimulation device for major depressive disorder.
Eli Lilly’s triple-G obesity readout; The latest Endpoints 100 results; Public biotechs cash in; and more
Welcome back to another edition of Endpoints Weekly. We’re barreling toward the holiday season, which means it’s time for an early programming note: Our newsletters


